"At some point this year, all these stocks were brutally slaughtered," Cramer said.» Read More
Our nation’s shortage of health care professionals is nothing to shout about. However, it generates demand.
A surge in interest in makers of security cameras drove shares of such companies higher, with heavy volume in particular seen in Digital Ally.
Shoe retailer DSW seems to have turned things around and its stock will likely march higher, says CNBC's Jim Cramer.
Goldman Sachs and Asian tech name, Baidu were in the "buy" category, while Netflix and utilities exchange-traded fund XLU were among the stocks to "sell."
Borrowing costs across Europe slid further this week, amid raised hopes of a Fed-style easing program to boost the euro zone's economies.
Investors are trying to get the S&P 500 Index through 2000 again, but I'm not sure there is a catalyst to keep it there given the mixed data.
Some of Tuesday's midday movers:
What have we learnt from the recent reporting flurry? Societe Generale has put together a list of conclusions to be drawn from this earnings season.
Helping millennials learn the benefits of compounding can be personally rewarding—and will help you establish a future client base.
With the S&P piercing 2000 intraday Monday, Cramer fully expects to hear nay-sayers single out the Fed. Can the rally endure?
Traders are watching to see if the S&P 500 can close above 2,000 Tuesday, as a meeting between Russia, Ukraine could be a wild card.
With declines of 30 percent year to date, you may be thinking about nibbling on these stocks. Cramer, however, says they're far from delectable.
Some of the names on the move ahead of the open.
The "Fast Money" traders share their final trades of the day.
People seek expert opinions when it comes to just about anything but their investments.
If you’re lamenting the recent decline in this stock, both Jim Cramer and the company’s CEO would like a word.
When it comes to fast food, McDonald’s is the Mac daddy. But on Wall Street the Golden Arches are getting a run for their money. USAToday reports.
The possibility of a new iPhone with a larger screen could be a game changer for Apple's stock, say some investors.
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
The S&P 500 index's crossing 2,000 for the first time is just an "item of note," says veteran trader Art Cashin.
Get the best of CNBC in your inbox